Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced preliminary Phase 2 trial results for RM-718, an investigational MC4R agonist, showing an 11.6% mean BMI reduction in acquired hypothalamic obesity patients at 16 weeks. The efficacy is comparable to existing treatments setmelanotide and bivamelagon, with notably reduced hyperpigmentation side effects (only 2 mild injection site cases). The company will discuss Q2 2026 financial results in a conference call.